TradeFlare's AI research teams analysed BLTE on 8 market nights between April 21, 2026 and September 30, 2026. Each row is that night's verdict, the price that day, and how the price actually moved afterwards — wins and misses alike. Nothing is edited after the fact.
| Date | Verdict | Price | Target / stop | 5 days later | 20 days later | Why (that night) |
|---|---|---|---|---|---|---|
| September 30, 2026 | HOLD | $166.66 | — / — | -8.1% | not yet | The current market and stock setup does not warrant a BUY. |
| September 29, 2026 | HOLD | $165.93 | $182.52 / $141.04 | -6.6% | not yet | The stock is in a neutral market regime, and while there are bullish fundamental and sentiment signals, the technicals are neutral, and the risk score is high. |
| September 28, 2026 | BUY | $167.33 | $198.42 / $142.23 | -4.1% | not yet | The PDUFA date for Tinlarebant is February 12, 2027, suggesting a medium-term catalyst. |
| September 9, 2026 | BUY | $192.85 | $231.42 / $163.92 | -7.6% | -14.8% | The PDUFA decision date for Tinlarebant is February 12, 2027, which is a significant catalyst within this timeframe. |
| August 28, 2026 | BUY | $157.01 | $174.00 / $131.75 | +27.6% | +9.4% | The stock is poised for a potential breakout above resistance, supported by strong fundamental and sentiment factors, with a medium-term outlook for the catalyst to play out. |
| August 27, 2026 | BUY | $156.69 | $172.50 / $131.75 | +9.0% | +6.6% | The FDA Priority Review catalyst for Tinlarebant provides a clear near-term catalyst window. |
| August 25, 2026 | BUY | $158.87 | $187.04 / $132.49 | -3.1% | +4.3% | The PDUFA date for Tinlarebant is February 12, 2027, suggesting a medium-term catalyst. |
| April 21, 2026 | HOLD | $165.43 | — / — | -3.9% | -15.4% |
Prices are daily closes. "Days later" counts trading days from the close on the day of the call. A HOLD is not a recommendation to buy; only published signals are tracked with a target and stop on the public record. How the research works. Updated October 14, 2026. AI-generated research for educational purposes — it can be wrong and is not financial advice.